Communiqués Catalent, Inc. Berne S.E.

Actions

0C8

US1488061029

Temps Différé Berne S.E. Autres places de cotation			Varia. 5j.	Varia. 1 janv.
- ^CHF	-.--%		-.--%	-

07/07	Nanoscope Therapeutics renforce son partenariat avec Catalent pour le développement de phase avancée et la production commerciale du MCO-010	CI
16/06	Catalent lance Qai, un outil d'intelligence artificielle d'entreprise dédié à la gestion de la qualité	CI

Communiqués

19/02/25	Experts explore the future of iPSC-based cell therapies	AQ
18/12/24	Catalent : Novo Holdings Completes Acquisition of Catalent Form 8 K	PU
18/12/24	Novo Holdings Completes Acquisition of Catalent	BU
16/12/24	Novo Nordisk A/S, The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close	AQ
16/12/24	Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction	AQ
16/12/24	Catalent : and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction Form 8 K	PU
14/12/24	Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction	BU
09/12/24	Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction	AQ
09/12/24	The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings	AQ
06/12/24	Catalent : and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction Form 8 K	PU
06/12/24	Catalent and Novo Holdings Receive European Commission Unconditional Approval for Pending Transaction	BU
05/11/24	Catalent: Fiscal Q1 Earnings Snapshot	AQ
05/11/24	Catalent : Reports First Quarter Fiscal 2025 Results Form 8 K	PU
05/11/24	Catalent, Inc. Reports First Quarter Fiscal 2025 Results	BU
29/10/24	Catalent : IsomAb Announces Strategic Collaboration with Catalent	PU
21/10/24	Catalent : Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings Form 8 K	PU
21/10/24	Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings	BU
14/10/24	Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility	BU
30/08/24	American Injectables CEO Beau Garrett Comments on the Catalent-Novo Transaction: A Catalyst for Competition and Innovation	AQ
29/08/24	Catalent: Fiscal Q4 Earnings Snapshot	AQ
29/08/24	Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results	BU
16/07/24	Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany	BU
07/06/24	Ardena appoints Jeremie Trochu as Chief Executive Officer	AQ
29/05/24	Catalent Stockholders Approve Transaction with Novo Holdings	BU
09/05/24	Catalent: Fiscal Q3 Earnings Snapshot	AQ